iBio, Inc..
IBIO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
iBio, Inc. is a biotechnology company focused on developing and manufacturing biopharmaceuticals using its proprietary plant-based iBioLaunch and Glycaneering technologies. The company's primary activities involve the research, development, and manufacturing of recombinant proteins for various appli...Show More
Better Health for All
0
iBio's core business is dedicated to developing biopharmaceuticals for serious diseases, including next-generation antibody treatments for hard-to-target cancers, obesity, cardiometabolic diseases, and vaccines for Lassa fever and COVID-19.
1
Its mission is to decrease drug failures, shorten development timelines, and improve efficacy and safety profiles, indicating a 100% focus on health-positive products.
2
The company's technology is designed to improve the safety profile of antibody treatments, aiming to reduce off-target effects and cytokine release.
3
iBio is developing treatments for vulnerable populations, such as a Lassa fever vaccine for endemic regions and exploring an anti-CD25 antibody for orphan diseases.
4
The company's annual report includes a 'Risk Factors' section detailing various business risks and forward-looking statements.
5
iBio invests heavily in health innovation, spending $5.2 million in R&D in fiscal year 2024, and leveraging AI, machine learning, and proprietary technologies for antibody discovery and optimization.
6
The company provides competitive wages, benefits, and a 401(k) plan to attract and retain key personnel.
7
iBio is developing vaccines for Lassa fever and COVID-19, demonstrating a focus on preventative health.
8
The company acknowledges its reliance on IT systems and vulnerability to cybersecurity risks and data leakage.
9
During the COVID-19 pandemic, iBio developed vaccine candidates and its FastPharming Facility® was part of the 'Blue Angel' initiative for rapid delivery of medical countermeasures.
10
Clinical trials are subject to FDA regulations, including good clinical practice, informed consent, and review by an independent institutional review board (IRB), with required annual progress and prompt safety reports for serious adverse events.
11
Fair Money & Economic Opportunity
0
iBio, Inc. is a biotechnology company focused on developing and manufacturing biopharmaceuticals. The company's core business activities do not involve lending, insuring, moving, or storing money, nor does it offer consumer financial products or services. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to iBio, Inc.'s operations, aligning with the '0' tier definitions in the rubric for companies outside the financial services sector.
1
Fair Pay & Worker Respect
20
iBio demonstrates strong employee engagement, with 87% of employees recommending working at the company, based on 36 Glassdoor reviews from 2022-2025.
1
The overall employee rating is 3.9 out of 5 stars, and compensation and benefits received a rating of 4.4 out of 5 stars.
2
The company offers medical, dental, and vision insurance options, along with life and disability insurance.
3
It also provides a 401(k) with a company match and flexible time off.
4
Fair Trade & Ethical Sourcing
0
No specific, concrete data points or explicit mentions regarding fair trade certifications, supplier audit frequency for ethical sourcing, substantiated forced or child labor incidents, supply chain traceability coverage, remediation speed for sourcing violations, ethical sourcing clauses in supplier contracts, share of spend on high-risk materials, or procurement budget directed to diverse suppliers were found across the provided articles. The articles primarily focus on financial performance, regulatory compliance related to product development and manufacturing (e.g., cGMP, GLP, GCP), intellectual property, and corporate governance, rather than ethical sourcing practices.
Honest & Fair Business
0
No specific, quantitative evidence was found across the provided articles for any of the KPIs related to Honest & Fair Business practices. The documents primarily consist of an Audit Committee Charter
1
and a license agreement
2
, which outline governance structures and contractual terms but do not provide data on regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification of ethical claims.
Kind to Animals
-60
iBio, Inc. utilizes a plant-based platform for producing biologics, indicating zero animal inputs for its core product lines. However, the company conducts preclinical studies using an obese rodent animal model and plans to rapidly advance testing in more complex animal models.
1
The company's R&D expenses were $5.185 million in 2024 and $10.327 million in 2023, but there is no specific evidence of investment in animal-free technologies.
2
iBio amended its existing collaboration agreement with AstralBio to add a fifth target for cardiometabolic disease, which is a general collaboration, not specifically focused on animal-free R&D.
3
No War, No Weapons
0
No evidence available to assess iBio, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data points were found across the provided articles to assess iBio, Inc. against the Planet-Friendly Business ethical value. Information regarding environmental performance, targets, certifications, or initiatives is not available in the evidence. Article 1 states the company believes it is in compliance with applicable environmental laws, regulations, permits, and licenses, but this is a statement of belief, not a factual report of zero violations.
1
Article 4 indicates a 'Low' SDG Transparency Score of 36.9 for the company as of May 1, 2024, but this is a qualitative assessment and not a direct measure for any specific KPI in the rubric.
2
Respect for Cultures & Communities
0
No data relevant to iBio, Inc.'s respect for cultures and communities was found in the provided articles. The articles focus on general biopharmaceutical industry news, financial profiles with no specific company data, press release aggregations, and iBio's drug discovery platform and pipeline, none of which contain information pertaining to community engagement, cultural impact, or related metrics.
Safe & Smart Tech
0
The provided articles do not contain specific, concrete data points or explicit information regarding any of the KPIs for the 'Safe & Smart Tech' ethical value.
1
Both articles explicitly state a lack of data or indicate that the metrics are not applicable for all relevant KPIs, such as data breach severity, cybersecurity investment, privacy certifications, AI ethics governance, and encryption implementation.
2
Therefore, no KPIs can be scored based on the evidence provided.
Zero Waste & Sustainable Products
-20
The company achieved a waste reduction rate of 68%.
1
It also tracks biannual waste data using online waste management tools.
2